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Figure S1. Study selection
Full-text articles assessed for eligibility (n=565)
Records identified through database search using terms "AngiotensinConverting enzyme inhibitor", "angiotensin receptor antagonist", and limited to RCT, Humans ( The required information size is based on an anticipated intervention effect of 15% relative risk reduction, a control event proportion estimated from the cumulated active controls event proportion, and a diversity = 0%, α=0.05 and β=0.10. Figure S4 . Trial sequential analysis (TSA) for the outcome of cardiovascular mortality.
The required information size is based on an anticipated intervention effect of 15% relative risk reduction, a control event proportion estimated from the cumulated active controls event proportion, and a diversity = 0%, α=0.05 and β=0.10. Figure S5 . Trial sequential analysis (TSA) for the outcome of myocardial infarction.
The required information size is based on an anticipated intervention effect of 20% relative risk reduction, a control event proportion estimated from the cumulated active controls event proportion, and a diversity = 0%, α=0.05 and β=0.10. Figure S6 . RASi versus placebo/active controls for the outcome of revascularization.
